Active ingredientTemsirolimusCat. No. P-T047-001CAS 162635-04-3Family · Pharmaceutical analytical standards
Temsirolimus
An mTOR inhibitor, a derivative and prodrug of sirolimus (rapamycin), approved in 2007 in the United States and Europe for advanced renal cell carcinoma. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Rapamycin, from which it derives, is named after Rapa Nui, Easter Island: the bacterium that produces it, Streptomyces hygroscopicus, was in soil samples collected on the island by a 1964-65 expedition.
Go to the active ingredient →Active ingredientTemsirolimusCat. No. P-T047-001CAS 162635-04-3
Isotopically labelledTemsirolimus-13C2-d7Cat. No. P-T047-002
Impurity7-O-Desmethyl TemsirolimusCat. No. P-T047-003CAS 408321-08-4
ImpurityTemsirolimus 7-O-Desmethyl ImpurityCat. No. P-T047-004
ImpurityTemsirolimus Impurity 1 (Temsirolimus Isomer C)Cat. No. P-T047-005CAS 1027067-40-8
ImpurityTemsirolimus Impurity 2Cat. No. P-T047-006CAS 162635-03-2
ImpurityTemsirolimus Impurity 3Cat. No. P-T047-007CAS 1401284-72-7
ImpurityTemsirolimus Impurity 4Cat. No. P-T047-008
ImpurityTemsirolimus Impurity 5Cat. No. P-T047-009
ImpurityTemsirolimus Impurity 6Cat. No. P-T047-010No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.